ABBOTT LABORATORIES — Director's Dealing 2021

Jul 6, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-07-01

Reporting Person: Morrone Louis H. (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	34465	Direct
Common shares without par value	2268	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$48.34	2027-07-09	Common Shares (29965)		Direct
Option (right to buy)	$59.94	2028-02-15	Common Shares (51559)		Direct
Option (right to buy)	$75.90	2029-02-21	Common Shares (38190)		Direct
Option (right to buy)	$87.72	2030-02-20	Common Shares (35469)		Direct
Option (right to buy)	$124.04	2031-02-18	Common Shares (22272)		Direct

Footnotes

F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 9,989 on July 10, 2018, 9,988 on July 10, 2019, and 9,988 on July 10, 2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019 and 17,186 on February 16, 2020, and an increment of 17,186 becomes exercisable on February 16, 2021.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 12,730 on February 22, 2020 and 12,730 on February 22, 2021, and an increment of 12,730 becomes exercisable on February 22, 2022.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 11,823 on February 21, 2021 and annual increments of 11,823 become exercisable on each of February 21, 2022 and February 21, 2023.

F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,424 on February 19, 2022, 7,424 on February 19, 2023 and 7,424 on February 19, 2024.